Cancer treatment device

Abstract

To provide a new cancer treatment device effective in treatment of cancer.SOLUTION: In a cancer treatment device 30, a treatment tool 32 is introduced to the vicinity of an affected part via a working channel of an endoscope. A deep ultraviolet LED 34 is arranged at a distal end 40 of the treatment tool 32, and emits deep ultraviolet rays to be applied to the affected part. An X-ray opaque marker 44 is arranged the distal end of the treatment tool. A control part 36 controls light emission of the deep ultraviolet LED. The control part 36 is arranged at a proximal end 42 of the treatment tool 32. A lead wire 38 connecting the deep ultraviolet LED 34 and the control part 36 is arranged inside the treatment tool 32.SELECTED DRAWING: Figure 2

Description

[Technical field]

[0001] The present invention relates to a device for treating cancer. [Background technology]

[0002] Endoscopic mucosal resection and endoscopic submucosal dissection are used as treatment methods for early esophageal cancer, gastric cancer, colon cancer, etc. In Japan, photodynamic therapy (PDT) in which a photosensitive substance is administered is being clinically applied to residual and recurrent esophageal cancer. In addition, photoimmunotherapy (NIR-PIT) in which a molecular targeted antibody drug is administered with a near-infrared photosensitive substance to accumulate in the cancer and then the cancer is killed with near-infrared light is under clinical development. As another example of phototherapy, Patent Document 1 discloses a method in which tumor cells are selectively killed by irradiating them with pulsed light (UV pulse flash) having a continuous emission spectrum with wavelengths of 230 to 270 nm. In the method of Patent Document 1, a xenon flash lamp is used as the light source for the UV pulse flash. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2011-78750 A Summary of the Invention [Problem to be solved by the invention]

[0004] Endoscopic mucosal resection and endoscopic submucosal dissection are not suitable for lesions with ulcers, and surgery may be required due to bleeding or perforation during endoscopic resection. Most gastrointestinal cancers are adenocarcinomas, which are generally considered to be ineffective for radiation therapy. In addition, photodynamic therapy (PDT) causes photosensitivity as a side effect of the photosensitive substances used, which places a heavy burden on patients. Therefore, an effective treatment for these has not yet been established.

[0005] The present disclosure has been made in light of these circumstances, and has an object to provide a new cancer treatment device that is effective in treating cancer. [Means for solving the problem]

[0006] One embodiment of the present disclosure is a cancer treatment device comprising a deep ultraviolet LED that emits deep ultraviolet light to irradiate an affected area. Effect of the Invention

[0007] According to the present disclosure, a new cancer treatment device that is effective in treating cancer can be provided. [Brief description of the drawings]

[0008] [Figure 1] FIG. 1 is a diagram illustrating a schematic configuration of a cancer treatment device according to a first embodiment. [Diagram 2] Fig. 2(a) is a diagram showing a schematic configuration of a cancer treatment device according to a second embodiment, and Fig. 2(b) is an enlarged diagram showing a schematic configuration of a distal end of the cancer treatment device according to the second embodiment. [Diagram 3] FIG. 13 is a schematic diagram showing a cancer treatment device according to a second embodiment for irradiating cancer with deep ultraviolet light. [Figure 4] FIG. 11 is an enlarged view showing a schematic configuration of a distal end of a cancer treatment device according to a modified example of the second embodiment. [Diagram 5] FIG. 1 shows changes in cell morphology caused by irradiation of human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 with deep ultraviolet light. [Figure 6] FIG. 1 shows the induction of apoptosis by deep ultraviolet light in human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1. [Figure 7] 7(a) and 7(b) show changes in protein expression in the human pancreatic cancer cell line KLM1 due to deep ultraviolet light irradiation. [Figure 8]Figure 8(a) shows the results of real-time PCR for TIMP1 expression in human pancreatic cancer cell line KLM-1. Figure 8(b) shows the results of real-time PCR for TSP1 expression in human pancreatic cancer cell line KLM-1. [Figure 9] FIG. 1 shows changes in the expression of YAP / TAZ in the human pancreatic cancer cell line KLM1. [Figure 10] These are photographs of tumors in a mouse subcutaneous carcinogenesis model on the 14th day after irradiation in a group irradiated once a week with deep ultraviolet light, a group irradiated once a week for two consecutive weeks with deep ultraviolet light, and a non-irradiated group. [Figure 11] 1 is a graph showing the change in tumor volume according to the number of deep ultraviolet irradiations in a mouse subcutaneous carcinogenesis model. [Figure 12] 1 is a graph showing the expression level of elastin analyzed by immunostaining. [Figure 13] 1 is a graph showing the expression level of collagen I analyzed by immunostaining. [Figure 14] 1 is a graph showing the expression level of collagen IV analyzed by immunostaining. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Hereinafter, embodiments for carrying out the present disclosure will be described in detail with reference to the drawings, etc. The embodiments are illustrative and do not limit the invention, and all of the features and combinations thereof described in the embodiments are not necessarily essential to the invention.

[0010] [First embodiment] Fig. 1 shows a schematic configuration of a cancer treatment device according to the first embodiment. As shown in Fig. 1, the cancer treatment device 10 includes a deep ultraviolet LED 12, a holding unit 14, a control unit 16, a conductive wire 18, and an imaging unit 20.

[0011] The deep ultraviolet LED 12 emits deep ultraviolet light to be irradiated to the affected area. The deep ultraviolet LED 12 has an LED structure in which nitride semiconductors made of GaN, InGaN, and AlGaN are grown in layers on a sapphire substrate, similar to the blue LED. The deep ultraviolet LED 12 is small, measuring a few mm in size, has a low operating voltage, and has zero warm-up time. Furthermore, the deep ultraviolet LED 12 has a long life. Therefore, the cancer treatment device 10 of this embodiment has the advantages of being small and consuming little energy.

[0012] Deep ultraviolet light is ultraviolet light with a relatively short wavelength of 250 to 350 nm, and has a cytotoxic effect. This is because DNA has an absorption wavelength peak for ultraviolet light at around 260 to 270 nm, and ultraviolet light of this wavelength causes mutations, causing two adjacent thymines or cytosines to dimerize, causing functional disorders such as cell division inhibition. Since deep ultraviolet light has a short wavelength, it is thought that the depth at which it can reach tissues is limited (for example, less than 2 mm from the mucosal epithelium), and its anticancer effect at deeper positions is limited, but in the present invention, it has been found that deep ultraviolet light has an anticancer effect on cancer tissues that exist at depths greater than that. Specifically, deep ultraviolet light acts not only on cancer cells themselves but also on fibrous components of tumors (elastin, collagen, etc.), reducing these fibrous components and shrinking tumors.

[0013] The wavelength of the deep ultraviolet light emitted by the deep ultraviolet LED 12 is preferably 350 nm or less, more preferably 250 to 300 nm, and further preferably 260 to 290 nm.

[0014] The output, number and size of the deep ultraviolet LEDs 12 can be appropriately selected depending on the location and size of the affected area. From the viewpoint of reliably obtaining the antitumor effect of deep ultraviolet rays, it is preferable to use an output of 2 mW / cm 2 It is preferable that the deep ultraviolet LED 12 is configured to irradiate the affected area with deep ultraviolet rays at an irradiance of deep ultraviolet rays of 5 to 300 seconds or more. The irradiance of deep ultraviolet rays is more preferably 2 to 7 mW / cm. 2For example, the illuminance at the center of the illuminance distribution formed by the deep ultraviolet LED 12 is set to be the illuminance applied to the affected area, and the illuminance at the center is set to 2 to 7 mW / cm. 2 The deep ultraviolet LED 12 can be configured so as to satisfy the above. The irradiation time of deep ultraviolet rays is more preferably 15 to 120 seconds, and further preferably 30 to 60 seconds. Although one irradiation is effective, two or more irradiations are preferable to ensure an antitumor effect. The interval between irradiations can be appropriately changed in units of hours, days, weeks, or months depending on the state of the tumor in the affected area and the effect on normal tissue.

[0015] The holding part 14 holds the deep ultraviolet LED 12 and fixes the deep ultraviolet LED 12 so that the deep ultraviolet ray can be irradiated from the vicinity of the affected area. The holding part 14 may have an elongated shape that can be inserted to the vicinity of the affected area inside the body. This allows the deep ultraviolet ray to be irradiated only to the affected area inside the body. The length of the holding part 14 can be adjusted so that the deep ultraviolet ray LED 12 reaches the vicinity of the affected area. The thickness of the holding part 14 can be adjusted according to the location of the affected area inside the body. For example, it can be made to have a thickness that can pass through a laparoscope port or the digestive tract.

[0016] In the first embodiment shown in FIG. 1, the deep ultraviolet LED 12 is disposed at one end (distal end) of the holding part 14. A control part 16 that controls the light emission of the deep ultraviolet LED 12 is disposed at the end (proximal end) opposite to the end of the holding part 14 where the deep ultraviolet LED 12 is disposed. Inside the holding part 14, a conductor 18 that connects the deep ultraviolet LED 12 and the control part 16 is disposed. The holding part 14 may be made of a hard material such as metal, or a soft material such as a resin fiber. In addition, a part of the holding part 14 may be curved. For example, the part close to the end of the holding part 14 where the deep ultraviolet LED 12 is disposed may be curved so that the deep ultraviolet light emitted by the deep ultraviolet LED 12 can be accurately directed to the affected area.

[0017] An imaging section 20 that outputs image information of the inside of the body as an electrical signal is disposed at the end of the holding section 14 where the deep ultraviolet LED 12 is located. The imaging section 20 may include an imaging element such as a CCD or a C-MOS. Based on the image information obtained from the imaging section 20, the position of the deep ultraviolet LED 12 at the tip of the holding section 14 relative to the affected area can be grasped, and the deep ultraviolet LED 12 can be positioned so as to face the affected area, thereby accurately irradiating the affected area with deep ultraviolet rays.

[0018] The cancer treatment device 10 according to the first embodiment can be used to treat various types of cancer, but is particularly useful for treating adenocarcinoma. As described above, deep ultraviolet light has not only a cytotoxic effect but also an antitumor effect that exceeds the degree of tissue penetration. This antitumor effect is particularly effective against adenocarcinoma.

[0019] The cancer treatment device 10 may be an endoscope. When the cancer treatment device 10 is an endoscope, a part of the holding part 14 is inserted into the body, starting from the distal end of the holding part 14 where the deep ultraviolet LED 12 and the imaging unit 20 are arranged. The distal end of the holding part 14 can be inserted to the vicinity of the affected area while viewing the inside of the body with the imaging unit 20. Then, the deep ultraviolet ray is irradiated from the deep ultraviolet LED 12 to the affected area, and the cancer can be treated. The type of endoscope is not particularly limited, and examples thereof include flexible endoscopes such as digestive endoscopes and rigid endoscopes such as laparoscopes.

[0020] [Second embodiment] FIG. 2(a) shows a schematic configuration of a cancer treatment device according to a second embodiment. FIG. 2(b) shows a schematic configuration of a distal end of a cancer treatment device according to a second embodiment. As shown in FIG. 2(a) and FIG. 2(b), a cancer treatment device 30 includes a treatment tool 32, a deep ultraviolet LED 34, a control unit 36, and a conductor 38.

[0021] The treatment tool 32 is wire-shaped and is introduced to the vicinity of the affected area through the working channel of the endoscope. The treatment tool 32 is made of a soft material such as a resin fiber. The size of the treatment tool 32 can be appropriately set so that it can pass through the working channel of the endoscope and its distal end can reach the vicinity of the affected area. For example, the longest width of the cross section of the treatment tool 32 is 2.7 mm or less.

[0022] As shown in Fig. 2(b), the deep ultraviolet LED 34 is disposed at the distal end 40 of the treatment tool 32. Cancer is often located within the wall of a tube in the body. Therefore, it is preferable that the deep ultraviolet LED 34 is disposed so as to emit deep ultraviolet light from the side of the treatment tool 32, so that the deep ultraviolet LED can be more reliably irradiated to the cancer.

[0023] As shown in Fig. 2(a), a control unit 36 ​​that controls the light emission of the deep ultraviolet LED 34 is disposed at the proximal end 42 of the treatment tool 32. As shown in Fig. 2(b), a conductor 38 that connects the deep ultraviolet LED 12 and the control unit 16 is disposed inside the treatment tool 32. The configurations of the deep ultraviolet LED 34, the control unit 36, and the conductor 38 can be the same as those of the deep ultraviolet LED 12, the control unit 16, and the conductor 18 in the first embodiment, respectively.

[0024] As shown in FIG. 2(b), a radiopaque marker 44 is disposed at the distal end 40 of the treatment tool 32. The radiopaque marker 44 is formed from a material that is not transparent to X-rays. Examples of such materials include metals such as gold, platinum, or tantalum, as well as barium sulfate, barium carbonate, halogen-containing compounds, or resins containing fillers (such as tricalcium phosphate or hydroxyapatite). The radiopaque marker 44 allows the position of the distal end 40 of the treatment tool 32 in the body to be easily confirmed under X-ray fluoroscopy. The position and shape of the radiopaque marker 44 at the distal end 40 of the treatment tool 32 are not limited to those shown in FIG. 2(b), and may be any position and shape that allows the position of the distal end 40 of the treatment tool 32 to be confirmed under X-ray fluoroscopy.

[0025] FIG. 3 is a diagram showing a schematic view of a cancer treatment device according to a second embodiment for irradiating a cancer with deep ultraviolet light. In FIG. 3, an endoscope 100, a duodenum 110, a pancreas 112, and a bile duct 114 are shown to explain the treatment of a cancer 120 by a treatment tool 32 of a cancer treatment device 30 according to the second embodiment. As shown in FIG. 3, the treatment tool 32 of the cancer treatment device 30 according to the second embodiment is introduced into the body through a working channel (not shown) of the endoscope 100. The tip of the endoscope 100 is introduced to the vicinity of a position where the duodenum 110 is connected to the bile duct. The distal end 40 of the treatment tool 32 is introduced from the tip of the endoscope 100 to the vicinity of a cancer 120 in the bile duct 114. The introduction of the distal end 40 is performed under X-ray fluoroscopy while checking the position of the distal end 40 in the body by a radiopaque marker 44 (not shown). The cancer 120 is treated by irradiating the cancer 120 with deep ultraviolet light A from a deep ultraviolet LED 34 (not shown) at the distal end 40 of the treatment tool 32. The cancer 120 in this embodiment is, for example, biliary tract cancer (bile duct cancer, gallbladder cancer).

[0026] [Variations] The cancer treatment device according to the second embodiment of the present disclosure includes a treatment tool, a deep ultraviolet LED, a control unit, a conductive wire, and an X-ray opaque marker, similar to the second embodiment. The same reference numerals are used for the components common to the cancer treatment device 30 according to the second embodiment, and duplicated descriptions are omitted as appropriate.

[0027] FIG. 4 shows a schematic configuration of the distal end of the treatment tool of the cancer treatment device according to the modified example of the second embodiment. The cancer treatment device 50 according to the modified example of the second embodiment is different from the cancer treatment device 30 shown in FIG. 2(b) in that the deep ultraviolet LEDs 54a, 54b, and 54c are arranged on the side of the treatment tool 32 so as to be aligned in a row in the introduction direction of the treatment tool 52 at the distal end 60 of the treatment tool 52. The deep ultraviolet LEDs 54a, 54b, and 54c are connected to the control unit 36 ​​(not shown) by a conductor 56. The X-ray opaque marker 44 is arranged on the distal end 60 of the treatment tool 52. By bending the side of the treatment tool 52 on which the deep ultraviolet LEDs 54a, 54b, and 54c are arranged, the deep ultraviolet rays emitted from the deep ultraviolet LEDs 54a, 54b, and 54c can be concentrated on the cancer. This makes it possible to more efficiently irradiate the cancer with deep ultraviolet rays and treat the cancer.

[0028] [Third embodiment] The cancer treatment method according to the third embodiment of the present disclosure includes a step of irradiating an affected area of ​​a subject with deep ultraviolet light emitted by a deep ultraviolet LED. According to this aspect, cancer can be effectively treated with energy saving by irradiating deep ultraviolet light using a deep ultraviolet LED.

[0029] The output, size and number of deep ultraviolet LEDs can be appropriately selected according to the illuminance required for treatment. The irradiation distance from the deep ultraviolet LED to the affected area can also be appropriately selected according to the illuminance required for treatment. From the viewpoint of accurately delivering deep ultraviolet rays to the affected area, the irradiation distance is preferably within 1 cm.

[0030] The wavelength, illuminance, irradiation time, number of irradiations, and irradiation intervals of deep ultraviolet rays can be set in the same manner as described in the embodiment of the cancer treatment device described above. In one embodiment of the cancer treatment method, it is preferable to use the cancer treatment device according to the above embodiment for irradiating the affected area of ​​the subject with deep ultraviolet rays.

[0031] In one embodiment of the method for treating cancer, the cancer may be any type of cancer, and is preferably adenocarcinoma. As described above, the antitumor effect of deep ultraviolet light is particularly effective against adenocarcinoma. EXAMPLES

[0032] The present embodiment will be described in more detail below with reference to examples, but these examples do not limit the present disclosure in any way.

[0033] Deep ultraviolet irradiation was performed using a prototype deep ultraviolet LED irradiation module from Nikkiso Co., Ltd. This module can irradiate deep ultraviolet rays of 250 to 350 nm, and the wavelength in the example is 285 nm. UVA irradiation was performed using a UVA irradiator (product name: ultraviolet LED (PW-UV943H-04), manufactured by Nichia Chemical Industries, Ltd.) that irradiates UVA with a wavelength of 375 nm. Since the deep ultraviolet irradiator and the UVA irradiator irradiate ultraviolet rays with different wavelengths, the illuminance was 6.7 mW / cm. 2 To achieve this, the irradiation distance was set to 3.0 cm for the deep ultraviolet irradiator and 4.7 cm for the UVA irradiator.

[0034] The human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 were obtained from the Medical Cell Resource Center, Institute of Development, Aging and Cancer, Tohoku University.

[0035] Example 1 Human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 were irradiated with deep ultraviolet light or UVA for 30 seconds, and the changes in cell morphology 24 hours after irradiation were observed using an all-in-one fluorescence microscope (product name: BZ-H4XD, manufactured by Keyence). Figure 5 shows the changes in cell morphology caused by irradiation of deep ultraviolet light on human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1. In all cases, the deep ultraviolet light-irradiated group showed deformation of the cell structure compared to the UVA-irradiated group and the unirradiated control group, and induction of cell death was confirmed.

[0036] Example 2 In this example, the apoptosis induction ability of deep ultraviolet rays on human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 was examined. The Muse (registered trademark) Annexin V and Dead Cell Kit (manufactured by Millipore) was used, and the manufacturer's protocol was followed. Figure 6 shows the induction of apoptosis in human pancreatic cancer cell lines KP-4, PANC-1, and KLM-1 by deep ultraviolet rays. After 30 seconds of irradiation of human pancreatic cancer cell lines with deep ultraviolet rays, 24 hours after irradiation, the deep ultraviolet irradiation group was 80.9% for KLM1, 92.1% for Panc1, and 88.0% for KP4, and apoptosis was significantly induced compared to the UVA irradiation group and the non-irradiated control group.

[0037] Example 3 To clarify the new mechanism of the antitumor effect of deep UV rays, we performed proteome analysis using the Angiogenesis Antibody Assay Kit (R&D systems) to examine changes in protein expression that are thought to be involved in angiogenesis and cancer invasion, rather than DNA damage. Proteome analysis was performed according to the manufacturer's protocol. Figures 7(a) and 7(b) show changes in protein expression in human pancreatic cancer cell line KLM1 by deep UV irradiation. In Figure 7(a), the area surrounded by a dotted circle shows the expression of TIMP1 (Tissue Inhibitor of Metalloproteinases 1) protein. Figure 7(a) shows that the expression of TIMP1 is suppressed by deep UV irradiation. TIMP1 is a protein that is thought to suppress extracellular organelle decomposition enzymes. In Figure 7(b), the area surrounded by a dotted circle shows the expression of TSP1 (Thrombospondin 1) protein, which is thought to be involved in the invasive ability of cancer. Figure 7(b) shows that the expression of TSP1 is suppressed by deep UV irradiation.

[0038] The expression of TIMP1 and TSP1 was also examined by real-time PCR. Real-time PCR was performed using TIMP1 primers (assay identification no. Hs99999139_m1; Applied Biosystems), TSP1 (THBS1) primers (assay identification no. Hs00962908_m1; Applied Biosystems), TaqMan universal PCR master mix (Applied Biosystems), and 7300 Fast Real Time PCR System (Applied Biosystems). 18S rRNA primers (assay identification no. Hs99999901_s1; Applied Biosystems) were used as an endogenous control. Figure 8(a) shows the results of real-time PCR for the expression of TIMP1 in the human pancreatic cancer cell line KLM-1. Figure 8(b) shows the results of real-time PCR for the expression of TSP1 in the human pancreatic cancer cell line KLM-1. As shown in Figures 8(a) and 8(b), significant suppression of expression of TIMP1 and TSP1 was observed in the deep ultraviolet ray-irradiated group compared to the UVA-irradiated group and the non-irradiated control group.

[0039] Example 4 It has been reported that TIMPs are related to YAP (Yes-associated protein) / TAZ (Transcriptional co-activator with PDZ-binding motif), which promotes cell proliferation and inhibits cell death. Therefore, the expression of YAP / TAZ in KLM1 was examined over time by Western blotting in the deep UV-irradiated group, UVA-irradiated group, and the control group (non-irradiated group). Western blotting was performed using YAP / TAZ antibody (8418S; Cell Signaling Technology), β-actin antibody (A5441; Sigma), and ChemiDoc™ Touch Imaging System (BIO RAD). Figure 9 shows the change in YAP / TAZ expression in the human pancreatic cancer cell line KLM1. YAP / TAZ expression almost disappeared 3 hours after irradiation of KLM1 with deep UV.

[0040] Example 5 A mouse subcutaneous carcinogenesis model was created by subcutaneously implanting pancreatic cancer cell line KLM1 as a tumor-bearing animal model. Specifically, 1x10 KLM1 cells were implanted subcutaneously in the thigh of nude mice (BALB / c: male, 8 weeks old). 7 The cells were mixed with 100 μl of cell matrix (Nitta Gelatin Co., Ltd.) and transplanted by subcutaneous injection. The size of the tumor was examined over time in the group irradiated with deep ultraviolet light once a week, the group irradiated with deep ultraviolet light twice a week for two consecutive weeks, and the control group (non-irradiated group). Figure 10 shows photographs of the tumors in the mouse subcutaneous carcinogenesis model on the 14th day of irradiation in the group irradiated with deep ultraviolet light once a week, the group irradiated with deep ultraviolet light twice a week for two consecutive weeks, and the non-irradiated group. Figure 11 is a graph showing the change in tumor volume in the mouse subcutaneous carcinogenesis model depending on the number of deep ultraviolet irradiations. Both the group irradiated with deep ultraviolet light once a week and the group irradiated with deep ultraviolet light twice a week for two consecutive weeks showed a tumor growth inhibitory effect compared to the control group (non-irradiated group). In addition, a tendency for tumor growth to be inhibited in the group irradiated with deep ultraviolet light once a week for two consecutive weeks compared to the group irradiated once a week was observed.

[0041] Example 6 The expression of elastin, collagen I, and collagen IV, which are involved in cell proliferation, was examined in subcutaneous tumors by immunohistochemistry using antibodies to elastin (AB213720; Abcam), collagen I (AB138492; Abcam), and collagen IV (ab6586; Abcam) and the Discovery XT automated slide preparation system (Ventana Medical Systems).

[0042] FIG. 12 is a graph showing the expression level of elastin analyzed by immunostaining. Significant suppression of expression was observed in the group irradiated with deep ultraviolet light once a week for two consecutive weeks. In this irradiation group, the expression of elastin was suppressed more than in the group irradiated once. FIG. 13 is a graph showing the expression level of collagen I analyzed by immunostaining. Similarly, the expression of collagen I was significantly suppressed in the group irradiated with deep ultraviolet light once a week for two consecutive weeks, and was suppressed more than in the group irradiated once. FIG. 14 is a graph showing the expression level of collagen IV analyzed by immunostaining. The expression of collagen IV was suppressed by deep ultraviolet light, but there was no significant difference between the group irradiated with deep ultraviolet light once a week for two consecutive weeks and the group irradiated once.

[0043] Studies on human pancreatic cancer cell lines and mouse subcutaneous carcinogenesis models showed that deep UV-LEDs had an antitumor effect. These results suggest the possibility of a new cancer treatment using deep UV-LEDs.

[0044] The present disclosure has been described above based on the embodiments. These embodiments are merely examples, and it will be understood by those skilled in the art that various modifications are possible in the combination of each component and each treatment process, and that such modifications are also within the scope of the present disclosure. [Explanation of symbols]

[0045] 30 cancer treatment device, 32 treatment tool, 34 deep ultraviolet LED, 36 control unit, 38 conductive wire, 40 distal end, 42 proximal end, 44 X-ray opaque marker.

Claims

1. A cancer treatment device comprising a deep ultraviolet LED that emits deep ultraviolet light to irradiate an affected area, the deep ultraviolet light having a wavelength of 285 to 350 nm.

2. The cancer treatment device according to claim 1, further comprising a treatment tool that is introduced to the vicinity of the affected area through a working channel of an endoscope, and the deep ultraviolet LED is disposed at a distal end of the treatment tool.

3. The cancer treatment device according to claim 2 , wherein the deep ultraviolet LED is arranged at a distal end of the treatment tool so as to emit deep ultraviolet light from a side surface of the treatment tool.

4. 4. The cancer treatment device according to claim 2, wherein the longest width of the cross section of the treatment tool is 2.7 mm or less.

5. 5. The cancer treatment device according to claim 2, further comprising an X-ray opaque marker, the X-ray opaque marker being disposed at a distal end of the treatment tool.

6. The cancer treatment device according to any one of claims 2 to 5, characterized in that the device includes two or more deep ultraviolet LEDs, and the two or more deep ultraviolet LEDs are arranged on the side of the treatment tool so as to be arranged in a row in the direction of introduction of the treatment tool.

7. The cancer treatment device according to any one of claims 2 to 6, further comprising a control unit for controlling the light emission of the deep ultraviolet LED, the control unit being arranged at a proximal end of the treatment tool, and a conductor connecting the deep ultraviolet LED and the control unit being arranged inside the treatment tool.

8. 2mW / cm ２ The cancer treatment device according to any one of claims 1 to 7, characterized in that the deep ultraviolet LED is configured to irradiate the affected area with deep ultraviolet light at an illuminance of deep ultraviolet light or higher for 30 to 60 seconds.

9. 9. The cancer treatment device according to claim 1, which is used for treating adenocarcinoma.

Images